enVVeno Medical Corporation (NASDAQ:NVNO) Shares Sold by Altium Capital Management LLC

Key Points

• Altium Capital Management LLC has significantly reduced its stock position in enVVeno Medical Corporation by 60.2%, now holding 123,256 shares, which represents 0.8% of its total portfolio.
• Other institutions like Jane Street Group and JPMorgan Chase have either bought new positions or increased their stakes in enVVeno Medical, indicating growing interest from institutional investors.
• Analysts have downgraded enVVeno Medical's rating from "hold" to "sell" and noted that the company reported a loss of ($0.33) earnings per share for the last quarter, missing estimates.

Altium Capital Management LLC reduced its stake in enVVeno Medical Corporation (NASDAQ:NVNO - Free Report) by 60.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 123,256 shares of the company's stock after selling 186,744 shares during the quarter. enVVeno Medical comprises approximately 0.8% of Altium Capital Management LLC's portfolio, making the stock its 16th biggest holding. Altium Capital Management LLC owned approximately 0.70% of enVVeno Medical worth $324,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in NVNO. Jane Street Group LLC purchased a new position in shares of enVVeno Medical in the 4th quarter worth about $56,000. Northern Trust Corp raised its holdings in shares of enVVeno Medical by 68.3% in the 4th quarter. Northern Trust Corp now owns 56,725 shares of the company's stock worth $171,000 after purchasing an additional 23,029 shares during the period. XTX Topco Ltd purchased a new position in shares of enVVeno Medical in the 1st quarter worth about $80,000. Geode Capital Management LLC raised its holdings in shares of enVVeno Medical by 20.6% in the 4th quarter. Geode Capital Management LLC now owns 181,737 shares of the company's stock worth $549,000 after purchasing an additional 31,061 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of enVVeno Medical in the 4th quarter worth about $147,000. 34.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded enVVeno Medical from a "hold" rating to a "sell" rating in a report on Saturday, August 9th.

enVVeno Medical Stock Performance

Shares of NVNO stock traded up $0.41 during trading hours on Friday, reaching $4.91. The company had a trading volume of 166,361 shares, compared to its average volume of 146,324. enVVeno Medical Corporation has a twelve month low of $2.03 and a twelve month high of $5.70. The company has a market capitalization of $94.52 million, a P/E ratio of -4.09 and a beta of 1.01. The stock's fifty day simple moving average is $4.48 and its 200 day simple moving average is $3.58.

enVVeno Medical (NASDAQ:NVNO - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05). As a group, equities analysts expect that enVVeno Medical Corporation will post -1.32 earnings per share for the current year.

About enVVeno Medical

enVVeno Medical Corporation Nasdaq: NVNO is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).